4/24
10:15 am
alxo
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]
Medium
Report
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]
4/24
10:00 am
alxo
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Medium
Report
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
4/12
10:08 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/11
11:41 am
alxo
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study [Yahoo! Finance]
Medium
Report
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study [Yahoo! Finance]
4/10
11:20 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
4/9
05:42 pm
alxo
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) [Yahoo! Finance]
Medium
Report
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) [Yahoo! Finance]
4/9
05:30 pm
alxo
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Low
Report
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
3/8
04:03 pm
alxo
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer [Yahoo! Finance]
High
Report
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer [Yahoo! Finance]
3/8
07:36 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $14.00 price target on the stock, up previously from $10.00.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $14.00 price target on the stock, up previously from $10.00.
3/7
11:14 pm
alxo
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending [Yahoo! Finance]
Medium
Report
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending [Yahoo! Finance]
3/7
04:09 pm
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/7
04:03 pm
alxo
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/5
04:43 pm
alxo
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting [Yahoo! Finance]
Neutral
Report
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting [Yahoo! Finance]
3/5
04:30 pm
alxo
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
Neutral
Report
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting